9780 Medical Center Drive
About GlycoMimetics, Inc.
GlycoMimetics is an oncology-focused biotechnology company. We are dedicated to improving the lives of patients by discovering, developing and commercializing novel, small-molecule glycomimetic product candidates.
Our management team consists of industry leaders with deep experience in the pharmaceutical/biotech industry.
Since our inception, we have developed a diversified product pipeline. Today, the company’s proprietary investigational drug for acute myeloid leukemia (AML) is being evaluated in two pivotal Phase 3 clinical trials.
222 articles with GlycoMimetics, Inc.
New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occlusive crisis (VOC) shows that patients treated with rivipansel within approximately 26 hours of the onset of pain in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placeb
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the upcoming Jefferies Virtual Healthcare Conference. The presentation will be available on the company’s website at the “Investors” tab for 30 days, beginning Thursday, June 4 from 1:00 – 1:25 p.m. EDT. To access the live webcast and subsequent archived recordings for the presentation, please
GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24.
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that its 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually instead of in person. Due to the ongoing public health impact of the COVID-19 pandemic and to support the health and well-being of the Company’s stockholders, employees and their families, the Company will hold the Annual Meeting via live audio webcast rather than as an in-person meet
GlycoMimetics, Inc., Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million.
Compelling Data on Mechanism of Action for GlycoMimetics’ Late-stage Clinical Candidate Uproleselan Published in Nature Communications
Research shows that uproleselan is a potent antagonist of E-selectin, can break chemoresistance
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its first quarter financial results on Friday, May 1, 2020, at 8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 4567397. A webcast replay will be available via the “Investors” tab on th
4/10/2020Biopharma companies strengthen their leadership teams and boards with this week's Movers & Shakers.
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that veteran regulatory expert Myra Rosario Herrle, PhD, RPh, RAC, has joined the executive management team as Vice President, Regulatory Affairs.
GlycoMimetics, Inc. announced that the compensation committee of the Company’s Board of Directors approved the grant on April 1, 2020 of non-qualified stock option awards to purchase an aggregate of 40,600 shares of its common stock to two new employees.
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the year and fourth quarter ended December 31, 2019 and highlighted recent company events including several accomplishments reported to date in 2020
Feb. 25, 2020 14:00 UTC ROCKVILLE, Md.--( BUSINESS WIRE )-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen and Company 40th Annual Health Care Conference in Boston, on Tuesday, March 03, 2020, at 12:00 p.m. ET. To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com . About GlycoMimetics
Feb. 4, 2020 14:53 UTC - US Composition of Matter Patent issued - Orphan Drug and Rare Pediatric Disease Designations granted by FDA for treatment of osteosarcoma
First Patient With Advanced Breast Cancer Receives First Dose in Clinical Trial of GlycoMimetics' GMI-1359
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Duke University investigators have dosed the first patient in a proof-of-concept Phase 1b study to evaluate GlycoMimetics' novel GMI-1359 drug candidate in patients with advanced breast cancer.
GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China
GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties
GlycoMimetics, Inc. announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York, which takes place on December 3, 2019.
GlycoMimetics, Inc. announced that company executives will provide a corporate update at two upcoming investor relations conferences in November.
Advanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials
GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that seven abstracts covering data from the company’s research and clinical portfolio have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2019 in Orlando.
The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.